VERAXA is a Swiss/German clinical-stage company advancing next-generation antibody therapies to fight cancer through groundbreaking innovations. Using a dual-targeting approach, our BiTAC-TCE, BiTAC-ADC, and bsADC platforms are powered by proprietary chemical bioconjugation and linker technologies.